The suboptimal efficacy of the currently available 23-valent pneumococcal vaccine in the growing population of adults ú65 years old may be related to the limited immunogenicity of the vaccine polysaccharides in this group. In this study, the majority of elderly outpatients with stable chronic illnesses generated a vigorous IgG response to seven vaccine serotypes comparable to that of healthy young adults at 1, 3, and 16 months after immunization. Moreover, the quality and function of anticapsular antibodies, measured as avidity and in vitro opsonization, were comparable between elderly and young subjects over time. However, a subset (Ç20%) of elderly outpatients responded to fewer than two of seven serotypes tested 1 and 3 months after immunization, whereas none of the healthy young adults were such poor responders. Thus, despite the adequate mean immune responses of the elderly as a group, a substantial proportion of elderly persons may have poor responses to the currently available pneumococcal vaccine.
Effective prevention of Streptococcus pneumoniae infection control studies. These studies have indicated variable and incomplete protection (60% -81%) from lethal disease among has renewed priority in an era in which the emergence of antibiotic-resistant strains has further compromised efforts to immunized elderly adults [6 -11] .
The variable efficacy of the pneumococcal vaccine in the reduce early mortality from invasive pneumococcal infection [1 -3] . Although the 23-valent pneumococcal polysaccharide elderly presumably reflects the poor immunogenicity of polysaccharide-based vaccines in this population. Measurements of (PPS) vaccine was formulated to prevent invasive infection in the elderly and other high-risk populations, the protective effi-PPS-specific serum antibodies after pneumococcal immunization of the elderly have produced conflicting results, possibly cacy of this vaccine for the growing population of adults ú65 years old remains uncertain. Doubts regarding the vaccine's because of differences in the selection of subjects (e.g., chronically ill or unusually healthy elderly) or controls (e.g., historical ability to prevent pneumococcal infection in this group were first raised by prospective randomized trials that did not detect controls or cohort) and in methods for assaying antibody concentrations [12 -20] . More importantly, measures of the quality significant reductions in the incidence of pneumococcal bronchitis, pneumonia, or bacteremia in immunized elderly adults of immune responses to pneumococcal vaccine in the elderly have been assayed in only a single report [19] , and the func- [4, 5] . However, these studies may have lacked sufficient statistical power to exclude the possibility of vaccine efficacy, due tional response to pneumococcal immunization has not been previously assessed. to the unexpectedly low frequency of pneumococcal infection during these trials. Because further clinical trials were not feasiTherefore, in order to establish the effectiveness of pneumococcal vaccination in elderly adults treated in an outpatient ble due to logistical difficulties and the ethical problems of denying high-risk elderly subjects a licensed and recommended primary care clinic, we measured concentrations of PPS-specific IgG in baseline sera and after immunization of elderly vaccine, vaccine efficacy was subsequently reevaluated in caseadults and healthy young subjects with the 23-valent vaccine.
In particular, we assayed specific IgG against a panel of PPSs, using a recently standardized ELISA method and standard ref- JID 1998; 178 (August) an on-site pneumococcal vaccine program. All elderly subjects A reference pooled human serum was standardized by comparison with the international standard serum 89-SF (gift of Carl were male, ambulatory, and free of acute illness at the time of Frasch, FDA, Bethesda, MD), for which the concentrations of vaccination. During this same period, healthy young adults õ35 vaccine type-specific IgG antibody have been established [24] . years old were enrolled as control subjects from the medical cenStandard concentrations of IgG antibody specific for type 25 in ter's research and house officer staff. A history of pneumonia the reference serum were assigned by a cross-standardization or a previous pneumococcal vaccination were the only exclusion method [25] . criteria. Medical histories and medication use data were obtained Purified capsular PPSs were bound to 96-well polystyrene mifrom patients and verified against the computerized hospital record.
crotiter plates (Nunc Maxisorp; PGC Scientifics, Gaithersburg, Patients were assigned medical co-morbidities if conditions were MD) at 0.5 mg/100 mL PBS per well by overnight incubation at listed as active medical problems in the medical record. Co-mor-4ЊC. Sera and standards were incubated with cell wall polysacchabidities included chronic cardiac diseases (congestive heart failure, ride (Statens Seruminstitut, Copenhagen) (10 mg/mL serum) at atherosclerotic coronary artery disease, and arrhythmias), chronic room temperature for 30 min with mixing to neutralize crossobstructive pulmonary disease (emphysema, chronic bronchitis, reacting antibodies. Serum samples were applied to plates at an and chronic asthma), diabetes mellitus (treated with oral agents or initial dilution of 1:200 in 1% bovine serum albumin with 0.05% insulin), chronic liver disease (cirrhosis, alcoholic liver, and (vol/vol) Tween-20 in PBS. IgG reactive with PPS was detected by chronic hepatitis), cancer (diagnosis of malignancy within 3 years, horseradish peroxidase-conjugated goat anti-human IgG (Jackson including lung, colon, prostate, and lymphoma), and chronic renal Laboratories, Bar Harbor, ME). Every microtiter plate included a failure (requiring dialysis).
positive laboratory reference and control serum that contained a Immunization and collection of sera. Each subject received an known level of IgG to the relevant PPS to assess the coefficient intradeltoid injection with 0. fold rise was calculated for each serotype for each subject at each after immunization. Sera were separated and stored at 070ЊC. All time. serum samples from elderly and young subjects at the indicated Determination of type 14-specific antibody avidity. Avidity times after immunization were collected before assays of capsule of IgG antibodies specific to the most prevalent serotype in bacter-PPS-specific IgG, antibody avidity, and opsonic activity were emic infections, type 14 PPS [22] , was assayed in duplicate as performed.
described [26, 27] . A laboratory reference serum was included on Total and differential leukocyte counts. A complete blood cell every plate to assess the coefficient of variation of measurement count with differential was performed on blood samples obtained between plates, and plates were repeated if the coefficient of variaprior to immunization. Lymphocyte subpopulation analysis was tion exceeded 15%. Results are expressed as avidity index, equal performed using flow cytometry (FACS 440; Becton Dickinson to the molarity of thiocyanate required to elute 50% of bound Immunocytometry Systems, San Jose, CA). Simultest reagents antibody under the condition of antigen excess. (mouse anti-human IgG1, IgG2a, CD14/CD45, CD3/CD4, CD3/ S. pneumoniae opsonization assay. Opsonization assays were CD8, and CD3/CD19; Becton Dickinson) were used following the performed in microtiter wells (Immulon I; Dynatech Laboratories, manufacturer's lysed whole blood protocol. Percent lymphocyte Chantilly, VA) essentially as described [28, 29] . Briefly, a fixed subpopulations were calculated by quadrant results with additional inoculum of log-phase S. pneumoniae (1000 cfu/well, ATCC 6314) white blood cell correction determined from CD45 staining in the was incubated in microwells with serial 1:2 dilutions of heatlymphocyte gate.
inactivated human sera (56ЊC for 30 min), 0.2 mg of complement Capsule PPS-specific IgG by ELISA. Levels of pneumococcal from a single screened lot (baby rabbit complement; Cederlane capsule-specific IgG were measured as previously described [21] .
Laboratories, Ontario, Canada), and 4 1 10 5 phagocytic cells (HLOn the basis of a review of pneumococcal serotypes producing 60, a myelomonocytic cell line, differentiated to a granulocyte line bacteremia in the United States [22] and at the Minneapolis VA using 120 mM dimethylformamide [30] ), yielding a granulocyte Medical Center over the past 5 years (unpublished data), we used effector-to-bacterial target ratio of 400:1. After rotation at 37ЊC as capture antigens purified capsular PPS (American Type Culture for 60 min, samples were plated and incubated on blood agar Collection, Rockville, MD) from common serotypes (types 14, 6B, plates. Results are reported as end-point titers giving 50% kill 8), less common serotypes (types 19F, 12F, 19A), and an uncomcompared with the number of viable organisms after incubation mon serotype (type 2) included in the 23-valent vaccine. Types with fetal calf serum, complement, and effector cells. A reference 14, 8, and 2 have the additional advantage of reproducible immunocontrol serum, with opsonic activity of 70% { 6%, was included genicity, as defined by a 2-fold increase in antibody titers across in each experiment. all studies of normal controls in a recent metaanalysis [23] . In Statistics. Differences in serum concentrations of capsule-speaddition, as a control for vaccine-specific immune responses, we cific IgG over time and between elderly and young groups were measured antibodies against serotype 25, which is not present in assessed using repeated measures of variance for comparisons the current 23-valent vaccine but was included in the previous 14- within groups and between groups. Associations between categoric variables were analyzed with x 2 analysis and continuous variables valent vaccine. the elderly (figure 1). Similarly, mean fold rises in PPS-specific using SPSS for Windows 6.1 (Chicago), and all P values were two-tailed.
IgG were generally comparable at each time between elderly and young groups, differing only for serotype 12F at 3 months (mean { SE Å 4.2 { .7 and 2.1 { .4 for elderly and young, respectively) Results and for serotype 14 at 16 months (2.5 { .3 and 4.1 { .8 for elderly and young, respectively). Because mean fold rise may not Clinical characteristics. The elderly subjects were, by intention, significantly older than the control subjects and were accurately represent differences in immune responses between populations, we further compared the proportions of elderly and on average regularly taking 2.4 medications for chronic health conditions, whereas control subjects were taking no medicayoung subjects who achieved at least a 2-fold increase in antibody levels for the serotypes and times tested (figure 2). Compared tions (table 1) . Because of the substantial differences in age and health status of the 2 groups, we first assessed whether the with elderly outpatients, the proportion of young control subjects with a 2-fold antibody rise was significantly greater only for elderly had significantly fewer peripheral blood immune cells than the young subjects. Whereas absolute neutrophil counts serotype 2 at 1 and 3 months after vaccination and for serotype 14 at 3 and 16 months after vaccination. Thus, for the majority were higher among the elderly outpatients than among the young adults, mean lymphocyte counts were similar in both of serotypes and times tested, comparable proportions of elderly and young subjects had significant immune responses to pneumoage groups (table 1). The distribution of lymphocyte subsets was also comparable among elderly and young subjects, includcoccal vaccine polysaccharides. Despite the similarities between age groups, we did identify ing the proportions of CD4
/ and CD8 / T cells and B lymphocytes (CD19 / ). Thus, the baseline total number and distribution individual subjects who were poor responders, defined very conservatively as those who mounted a 2-fold increase in capof immune cells in the blood of elderly outpatients were comparable to those of healthy young adults.
sule-specific IgG to õ2 of 7 serotypes at both 1 and 3 months after vaccination. A significant proportion of elderly outpatients Immune response to pneumococcal vaccine. Prior to immunization, concentrations of antibody to the seven serotypes were identified as poor responders (20.4%), whereas none of the young subjects were poor responders (comparison by x 2 , were similar between the 2 groups, although elderly outpatients had significantly higher mean concentrations of serotype 14 -P Å .05). In attempting to define clinical characteristics that would specific IgG (figure 1). Following immunization, both elderly outpatients and healthy young control subjects had robust antiidentify poor responders among the elderly outpatients, we compared age, underlying chronic diseases (cardiac, pulmoanalysis identified malignancy (risk ratio Å 2.64, P Å .01) and daily use of an angiotensin-converting-enzyme inhibitor (risk nary, liver, renal, and collagen-vascular), and medications. Within the group of elderly outpatients, poor responders were ratio Å 4.16, P Å .0002) as the only two independent risk factors for poor response to pneumococcal vaccine among these slightly older than responders (73.2 { 1.1 vs. 70.3 { .8, respectively, P Å.07). Of 18 variables analyzed, logistic regression patients. In summary, the magnitude and duration of PPS -specific Avidity of IgG responses to PPSs. Although an increase in concentrations of antigen-specific antibodies is fundamental for antibody responses of the group of elderly outpatients was similar overall to that of healthy young adults at 1, 3, and 16 effective immune response to vaccine, avidity, an expression of the functional antibody affinity [26] , reflects the quality of months after immunization with the 23-valent vaccine. However, a subset of elderly outpatients was identified as poor antibody produced, which correlates with the protective efficacy of antibodies [31] . Increasing antibody avidity over time responders to the panel of serotypes tested, whereas none of this small group of young subjects showed a similarly poor characterizes antibody maturation to some antigens, in association with increasing biologic activity (e.g., viral neutralization immune response. or bacterial killing). Our analysis of the avidity of PPS-specific IgG for serotype 14, the most prevalent serotype causing invasive pneumococcal disease, showed that the majority of baseline IgG samples from elderly and young subjects had comparable avidity indices (figure 3). Following immunization, type 14 PPS -specific antibody avidity did not increase over time for the majority of elderly and young subjects, indicating an absence of detectable antibody maturation for this antigen in our subjects. However, among subjects with ú2-fold increases in type 14 PPS -specific IgG after immunization, 4 of 40 elderly responders tested but 0 of 15 young responders showed an appreciable rise in avidity at 1 -3 months after vaccination. Thus, the avidity index of type 14 PPS -specific antibody can occasionally increase after antigen exposure, even in the elderly.
Functional activity of capsule-specific antibodies. Because the protective efficacy of the pneumococcal vaccine against invasive disease entails production of serum antibodies that support opsonophagocytosis and killing of S. pneumoniae, we determined the ability of sera to support opsonization of type 14 S. pneumoniae in vitro following immunization (figure 4). Similar to results by ELISA, a significant rise in mean opsonic titers after immunization was seen for both elderly and young subjects. Also, for the combined group of elderly and young adults, the ''specific opsonic activity'' of serum (opsonic activity per unit of antibody, corresponding to the slope of the regression line) appeared to increase after immunization (figure 4). We further evaluated the specific opsonic activity in the presence of pre-and postvaccination sera by calculating a ratio of opsonic activity per concentration of type 14 PPS -specific IgG for each subject's serum samples ( figure 5 ). For the combined group of elderly and young adults, mean specific opsonic activity increased significantly at 1 month after immunization and was sustained at 3 and 16 months ( figure 5A) . Similarly, the group of elderly outpatients had significantly increased mean serum-specific opsonic activity at 1 and 3 months after immunization. The group of young adults had higher mean specific opsonic activity than did elderly outpatients before and after immunization. However, because of greater variability in their values, the postimmunization specific opsonic activity of serum from young adults did not differ significantly from preimmunization values or from those of elderly outpatients (figure 5A). Thus, elderly and young adults had generally comparable increases in functional antibody response after immunization.
In contrast, the subset of poor responders to type 14 PPS had an appreciably decreased functional antibody response. For at either 1 or 3 months after vaccination, and an adequate B, mean { SE for groups of elderly and young subjects.
response was a 2-fold increase in specific antibody at either time. The 21 poor responders to type 14 PPS represented 19 (38%) of 50 elderly outpatients and 2 (13%) of 15 young to type 14, on the other hand, did not significantly increase specific opsonic activity at any time after immunization. In healthy adults. Adequate responders had significant increases in specific opsonic activity at 1 month after vaccination that fact, mean specific opsonic activity of serum at 16 months after immunization was slightly lower than the preimmunization were sustained at 3 and 16 months (figure 5B). Poor responders value for this group (figure 5B). Thus, although the functional antibody levels at 3 and 16 months after immunization that were significantly elevated over prevaccination titers. Moreantibody response to pneumococcal immunization of groups of elderly and young adults was comparable, a subset of poor over, the quality of anti-PPS antibodies, measured as avidity and in vitro opsonic activity, was comparable between elderly responders showed a distinctly reduced functional antibody response.
and young subjects over time. Thus, we demonstrated that the quantity, durability, and functional activity of antibody reIn summary, the quantity and quality of immune responses to pneumococcal immunization, measured as antibody level, sponses to pneumococcal polysaccharide vaccine in a group of elderly outpatients was similar to that of healthy young adults. avidity, and opsonic activity, were similar between elderly outpatients and healthy young control subjects. Although immuniDespite the comparable immune responses between groups of elderly and young subjects, we identified a subset of elderly zation did not significantly improve the avidity of anti-PPS antibodies, postvaccination serum of elderly outpatients and individuals who responded to õ2 of 7 serotypes tested at 1 and 3 months after immunization. In contrast, none of a small adequate vaccine responders did have significantly better functional activity in an in vitro opsonization assay. An identifiable group of healthy young adults in our study was a poor responder to the panel of serotypes tested. Musher et al.
[32] have presubset of elderly outpatients had poor antipneumococcal response by ELISA, and results were confirmed for serotype 14 viously reported that 11% of healthy adults, without regard to age, are poor responders to the 23-valent pneumococcal vacby opsonization assays.
cine. The discrepancy between their results and ours may reflect the small number of control subjects in our study or the differDiscussion ences between criteria used to define poor responders in the two studies. For example, Musher et al.
[32] defined low reWe report that the majority of elderly outpatients with stable chronic illnesses followed in a primary care clinic had a vigorsponders as subjects who produced a 2-fold increase in PPSspecific IgG at 1 month to £50% (5/10) of the vaccine seroous immune response to pneumococcal vaccine comparable to that of healthy young adults, as has been shown recently [14, types tested. In contrast, we used more lenient criteria to define poor responders as subjects who generated 2-fold increases in 15]. By 1 month after immunization, elderly outpatients had significantly increased mean concentrations of PPS-specific PPS-specific IgG at both 1 and 3 months to õ30% (2/7) of the vaccine serotypes tested. Conceivably, more of the healthy IgG to all vaccine serotypes tested, with absolute increases and fold rise in IgG generally comparable to those of healthy young adults studied by Musher et al. Comparison of specific opsonic activity of serum from elderly subjects (l), young subjects (᭺), and combined group (᭡). B, Comparison of specific opsonic activity of serum from adequate responders (subjects with at least 2-fold increase in type 14 PPS -specific IgG at either 1 or 3 months after vaccination, ) with that of poor responders (õ2-fold antibody response at both 1 and 3 months, ᮀ). *P õ .05 for comparison with preimmunization values (0 months).
[32] identified 89% of subjects as responders to PPS 14, comstudy. Nevertheless, our findings indicate that a substantial proportion of elderly individuals may have poor responses to pared with only 62% of our elderly subjects, consistent with the hypothesis that aging and associated conditions may, in fact, pneumococcal vaccine, despite the adequate mean immune responses of the elderly as a group, and suggest that these poor play a role in immune responses to pneumococcal vaccination. Although by design the groups of elderly and young subjects responders may have identifying clinical characteristics that should be further defined. in our study differed significantly in age, the mean age of the elderly poor responders was not significantly different from Several earlier studies of immune responses, particularly in elderly subjects, may have been confounded by measuring cell that of elderly with more robust immune responses. Furthermore, age did not emerge from logistic regression analysis as wall polysaccharide antibodies along with capsule-specific antibodies [12, 13, 17 -19] . Pneumococcal cell wall polysacchaa predictor of poor response to pneumococcal immunization. Two clinical predictors were identified by logistic regression, rides are highly immunogenic; however, in contrast to capsular PPS -specific IgG, antibodies to cell wall PPSs are not proteca diagnosis of malignancy and use of angiotensin-convertingenzyme inhibitor, which were associated with poor vaccine tive against invasive pneumococcal infection [20, 35, 36] . Accurate determination of protective immune responses to pneuresponse in our study population. We caution that the clinical applicability of such predictors identified post hoc by logistic mococcal vaccination therefore requires assay of capsule PPSspecific antibodies. Unfortunately, commercial pneumococcal regression is limited by the relatively small number of patients in this study and by any unique characteristics of our study vaccines and polysaccharides are now known to be contaminated with up to 50% cell wall PPSs and thus will induce population. Previous studies in the elderly have associated poor pneumococcal vaccine immune responses with female gender cell wall antibodies after vaccination and will bind nonspecific antibodies when used as capture antigens in ELISAs. As an [15, 33] and low serum levels of vitamin B12 [34] . All of our elderly outpatients were male, and serum B12 levels were not additional confounder, elderly and young subjects may have varying amounts of cell wall PPS antibodies prior to vaccinameasured in our study. Thus, we cannot compare the relative importance of these parameters with those identified in our tion. Anti -cell wall PPS antibodies have been detected in 99% In summary, our findings suggest that pneumococcal vaccination is effective in the majority of elderly men with chronic cell wall PPSs before assay of serotype-specific antibodies is not used. stable health problems in producing antibody responses that are quantitatively and functionally similar to those of young, Variability in apparent pneumococcal vaccine immunogenicity in earlier studies may also be due to the use of RIA rather healthy adults. Taken together with previous reports of vaccine efficacy and immunogenicity, our findings strongly support the than ELISA methodology to measure pneumococcal antibodies [13, 17, 18] . In contrast to ELISA, RIAs cannot distinguish uniform immunization of this high-risk group with the current available 23-valent vaccine. However, our study also demonantibody responses by IgM, IgG, and IgA immunoglobulin subtypes [23] . Consequently, RIA detection of immunoglobulin strates that a subset of these elderly have very poor immune responses to the current pneumococcal vaccine and may not isotypes other than IgG may have obscured apparent immune responses in some previous studies.
be protected. The variable and incomplete protective efficacy previously reported for pneumococcal immunization in the elOur study is unique among these previous studies of pneumococcal immunization of the elderly in that we assessed the derly may reflect variable numbers of poor responders included in such studies [6 -11] . functional activity of vaccine-derived antibodies by both avidity and opsonization assays. In the sole previous report of Because of the anticipated poor performance of polysaccharide-based vaccines in the elderly and other high-risk groups, antibody avidity after vaccination of elderly subjects, Konradsen [19] found no significant differences between antibody conjugate vaccines of pneumococcal oligosaccharides coupled with protein adjuvants have been constructed to improve immuavidity and type of PPS, vaccination status, age, or antibody level in 15 elderly adults (60 -67 years old). Our larger study nogenicity, similar to successful polysaccharide-protein conjugate vaccines developed for H. influenzae. To date, however, confirmed that type 14 PPS antibody avidity did not differ significantly between elderly and young subjects and did not these vaccines have not been found to be more immunogenic in the elderly than the current 23-valent vaccine [37, 38] . Given correlate with IgG concentration. Our results also confirmed that for most patients, avidity of type 14 PPS -specific IgG our results indicating that the 23-valent vaccine is quite immunogenic for the majority of elderly adults, the ''failure'' of does not increase from baseline values over 16 months after vaccination. Progressive increases in antibody avidity (affinity these newer pneumococcal vaccines may reflect an inappropriate selection of study subjects or vaccine serotypes. Our findmaturation), which are thought to represent selection of B cell clones expressing higher affinity antibodies, after vaccination ings suggest that a subset of elderly adults, potentially with identifiable clinical characteristics, respond quite poorly to with some protein antigens may also be associated with increased neutralizing activity [26, 27] . Although we did not find pneumococcal immunization with the current vaccine. Future studies will determine the clinical characteristics that define biochemical evidence of antibody maturation after immunization with PPSs, the functional ability of these antibodies to kill this population of poor responders among the elderly and target this population for investigation of new and improved pneumothe organism did appear to increase, as reflected by the opsonic activity per microgram of specific IgG. coccal vaccine strategies. We report for the first time the impact of pneumococcal vaccine on in vitro opsonic activity specifically in the elderly.
